{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:12559"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:12559","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Investigating the immunosuppressive microenvironment created by acute myeloid leukaemia using invariant natural killer T cells as a novel therapeutic approach","abstract":"Acute myeloid leukaemia (AML) creates an immunosuppressive microenvironment to conventional T cells through Arginase 2 (ARG2) inducing arginine depletion. We identify that AML blasts release the acute phase protein serum amyloid A (SAA), which acts in an autocrine manner to upregulate ARG2 expression and activity and promote AML blast viability. Invariant natural killer T cells (iNKT) are a distinct population of T-cells with the unique ability to bridge the innate and adaptive immune system by mediating a range of immune responses and play a key role in tumour immunosurveillance. In AML the low level of iNKT cells post stem cell transplant is associated with poor overall survival; however it is unclear if iNKT cells directly regulate the growth of malignant cells. We establish that iNKT cells can detect and interact with AML blasts in a CD1d/CD40 dependent manner. α-GalCer-loaded AML blasts induce potent iNKT cell activation resulting in release IFN-γ and initiating clonal expansion in vivo and in vitro. Activated iNKT cells can reduce tumour burden by directly killing AML blasts via granzyme B pathway inducing apoptosis. Despite the low arginine AML microenvironment which is hostile to T cells, iNKT cells retain their ability to proliferate, become activated and elicit a cytotoxic response against AML due to the upregulation of LAT-1 and ASS-1 dependent amino acid pathways. Finally, activated iNKT cells can further restore T cell proliferation both in vitro and in vivo. This illustrates that iNKT cells are key players in creating an anti-leukemic response, thus, stimulation of iNKT cell activity has the potential to be exploited as an immunotherapeutic approach against AML or as an adjunct to boost antigen-specific T cell immunotherapies in cancers.","abstract_html":"Acute myeloid leukaemia (AML) creates an immunosuppressive microenvironment to conventional T cells through Arginase 2 (ARG2) inducing arginine depletion. We identify that AML blasts release the acute phase protein serum amyloid A (SAA), which acts in an autocrine manner to upregulate ARG2 expression and activity and promote AML blast viability. Invariant natural killer T cells (iNKT) are a distinct population of T-cells with the unique ability to bridge the innate and adaptive immune system by mediating a range of immune responses and play a key role in tumour immunosurveillance. In AML the low level of iNKT cells post stem cell transplant is associated with poor overall survival; however it is unclear if iNKT cells directly regulate the growth of malignant cells. We establish that iNKT cells can detect and interact with AML blasts in a CD1d/CD40 dependent manner. α-GalCer-loaded AML blasts induce potent iNKT cell activation resulting in release IFN-γ and initiating clonal expansion in vivo and in vitro. Activated iNKT cells can reduce tumour burden by directly killing AML blasts via granzyme B pathway inducing apoptosis. Despite the low arginine AML microenvironment which is hostile to T cells, iNKT cells retain their ability to proliferate, become activated and elicit a cytotoxic response against AML due to the upregulation of LAT-1 and ASS-1 dependent amino acid pathways. Finally, activated iNKT cells can further restore T cell proliferation both in vitro and in vivo. This illustrates that iNKT cells are key players in creating an anti-leukemic response, thus, stimulation of iNKT cell activity has the potential to be exploited as an immunotherapeutic approach against AML or as an adjunct to boost antigen-specific T cell immunotherapies in cancers.","abstract_has_math":false,"creators":["Stavrou, Victoria"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-07","date_published":"2022-07","updated_at":"2026-11-19T09:31:48Z","subjects":["Q Science (General)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/12559/7/Stavrou2022PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A12559","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Stavrou, Victoria"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-07-14"]},{"key":"dc:date.issued","label":"Date","values":["2022-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/12559/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Q Science (General)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/12559/7/Stavrou2022PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Acute myeloid leukaemia (AML) creates an immunosuppressive microenvironment to conventional T cells through Arginase 2 (ARG2) inducing arginine depletion. We identify that AML blasts release the acute phase protein serum amyloid A (SAA), which acts in an autocrine manner to upregulate ARG2 expression and activity and promote AML blast viability. Invariant natural killer T cells (iNKT) are a distinct population of T-cells with the unique ability to bridge the innate and adaptive immune system by mediating a range of immune responses and play a key role in tumour immunosurveillance. In AML the low level of iNKT cells post stem cell transplant is associated with poor overall survival; however it is unclear if iNKT cells directly regulate the growth of malignant cells. We establish that iNKT cells can detect and interact with AML blasts in a CD1d/CD40 dependent manner. α-GalCer-loaded AML blasts induce potent iNKT cell activation resulting in release IFN-γ and initiating clonal expansion in vivo and in vitro. Activated iNKT cells can reduce tumour burden by directly killing AML blasts via granzyme B pathway inducing apoptosis. Despite the low arginine AML microenvironment which is hostile to T cells, iNKT cells retain their ability to proliferate, become activated and elicit a cytotoxic response against AML due to the upregulation of LAT-1 and ASS-1 dependent amino acid pathways. Finally, activated iNKT cells can further restore T cell proliferation both in vitro and in vivo. This illustrates that iNKT cells are key players in creating an anti-leukemic response, thus, stimulation of iNKT cell activity has the potential to be exploited as an immunotherapeutic approach against AML or as an adjunct to boost antigen-specific T cell immunotherapies in cancers."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Investigating the immunosuppressive microenvironment created by acute myeloid leukaemia using invariant natural killer T cells as a novel therapeutic approach"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Stavrou, Victoria"],"dc:date":["2022-07-14"],"dc:date.issued":["2022-07"],"dc:description.abstract":["Acute myeloid leukaemia (AML) creates an immunosuppressive microenvironment to conventional T cells through Arginase 2 (ARG2) inducing arginine depletion. We identify that AML blasts release the acute phase protein serum amyloid A (SAA), which acts in an autocrine manner to upregulate ARG2 expression and activity and promote AML blast viability. Invariant natural killer T cells (iNKT) are a distinct population of T-cells with the unique ability to bridge the innate and adaptive immune system by mediating a range of immune responses and play a key role in tumour immunosurveillance. In AML the low level of iNKT cells post stem cell transplant is associated with poor overall survival; however it is unclear if iNKT cells directly regulate the growth of malignant cells. We establish that iNKT cells can detect and interact with AML blasts in a CD1d/CD40 dependent manner. α-GalCer-loaded AML blasts induce potent iNKT cell activation resulting in release IFN-γ and initiating clonal expansion in vivo and in vitro. Activated iNKT cells can reduce tumour burden by directly killing AML blasts via granzyme B pathway inducing apoptosis. Despite the low arginine AML microenvironment which is hostile to T cells, iNKT cells retain their ability to proliferate, become activated and elicit a cytotoxic response against AML due to the upregulation of LAT-1 and ASS-1 dependent amino acid pathways. Finally, activated iNKT cells can further restore T cell proliferation both in vitro and in vivo. This illustrates that iNKT cells are key players in creating an anti-leukemic response, thus, stimulation of iNKT cell activity has the potential to be exploited as an immunotherapeutic approach against AML or as an adjunct to boost antigen-specific T cell immunotherapies in cancers."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/12559/7/Stavrou2022PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/12559/"],"dc:subject":["Q Science (General)"],"dcterms:accessrights":["public"],"dc:title":["Investigating the immunosuppressive microenvironment created by acute myeloid leukaemia using invariant natural killer T cells as a novel therapeutic approach"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:31:48Z"}